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Background: Four international study groups undertook a large study in resectable osteosarcoma, which included two
randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based on histo-
logical response.
Patients and methods: Patients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen,
comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m2, doxorubicin 75 mg/m2, methotrexate 12 g/m2 × 2
(MAP) and post-operatively two further cycles of MAP and two cycles of just MA. Patients were randomised after surgery.
Those with ≥10% viable tumour in the resected specimen received MAP or MAP with ifosfamide and etoposide. Those with
<10% viable tumour were allocated to MAP or MAP followed by pegylated interferon. Longitudinal evaluation of quality of life
was undertaken.
Results: Recruitment was completed to the largest osteosarcoma study to date in 75 months. Commencing March 2005,
2260 patients were registered from 326 centres across 17 countries. About 1334 of 2260 registered patients (59%) were ran-
domised. Pre-operative chemotherapy was completed according to protocol in 94%. Grade 3–4 neutropenia affected 83%
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of cycles and 59% were complicated by infection. There were three (0.13%) deaths related to pre-operative chemotherapy.
At deﬁnitive surgery, 50% of patients had at least 90% necrosis in the resected specimen.
Conclusions: New models of collaboration are required to successfully conduct trials to improve outcomes of patients with
rare cancers; EURAMOS-1 demonstrates achievability. Considerable regulatory, ﬁnancial and operational challenges must be
overcome to develop similar studies in the future.The trial is registered as NCT00134030 and ISRCTN 67613327.
Key words: osteosarcoma, randomised controlled trial, trial conduct, international collaboration
introduction
Osteosarcoma is the commonest primary bone cancer affecting
young people with an overall age-standardised incidence rate of 5.2
cases/million [1]. Cure of osteosarcoma in a proportion of patients
was consistently reported ﬁrst in the 1970s, achieved through the
combination of surgical extirpation of the primary tumour with
multi-drug chemotherapy. The results were further improved
during the next decade, but since then, no clinically signiﬁcant
advances have been made in survival, although more patients
access combination chemotherapy within and outside trials.
In 2001, four clinical study groups agreed to collaborate to conduct
osteosarcoma studies more rapidly. EURAMOS (European and
American Osteosarcoma Studies) was formed from the Children’s
Oncology Group (COG), Cooperative Osteosarcoma Study Group
(COSS) of the German Society for Pediatric Oncology and
Hematology (GPOH), European Osteosarcoma Intergroup (EOI)
and Scandinavian Sarcoma Group (SSG).
The EURAMOS group aimed to improve outcomes in osteo-
sarcoma, principally through large international, collaborative
randomised, controlled trials (RCTs). Additional objectives
were to facilitate biological research in osteosarcoma, more
rapidly identify new therapeutic approaches and develop a
common understanding and methodologies for staging, path-
ology and other aspects of disease management [2].
The ﬁrst study, EURAMOS-1, began recruitment in 2005 and
closed registration in June 2011. Good histological response,
assessed in the resected tumour, has been associated with
improved survival [3–5]. Therefore, this study addressed separate
treatment questions based on histological response. EURAMOS-
1 was notable for addressing randomised questions in a rare
cancer on an unprecedented scale and for launching at a time of
profound change to European legislation related to trial regula-
tion and governance [6]. We describe the study, its population
and the initial treatment of 2260 registered patients.
methods
patients
We designed a clinical trial to include patients with newly diagnosed localised
or metastatic osteosarcoma (see supplementary Material, available at Annals of
Oncology online) of the extremity or axial skeleton deemed to be suitable for
complete resection of all disease sites. Patients were aged ≤40 years at diagnos-
tic biopsy and had to both register on the study and start chemotherapy within
30 days after diagnostic biopsy. Patients required adequate bone marrow func-
tion (neutrophils ≥0.5 × 109/l or WBC ≥3 × 109/l; platelet count >100 × 109/l);
renal function (glomerular ﬁltration rate ≥70 ml/min/1.73 m2); liver function
(bilirubin ≤1.5 × upper limit of normal); cardiac function (shortening fraction
≥28% or ejection fraction ≥50%) and performance status (Karnofsky score
≥60; WHO performance status ≤2; or Lansky score ≥60%). Standard staging
and organ function investigations were undertaken.
Diagnostic biopsies were to be examined by local institutional pathologists
and reviewed by each study group’s reference pathologists.
study design
Figure 1 shows the design with randomisation deﬁned by histological response
in the primary tumour after pre-operative chemotherapy. Response classiﬁca-
tion was dichotomised: ≥90% necrosis (good response); <90% necrosis (poor
response). Registered patients were offered randomisation when also had:
completed two courses of cisplatin and doxorubicin pre-operatively; com-
pleted ≥2 (but ≤6) courses of methotrexate pre-surgery; recovered fully from
prior therapy; no disease progression; undergone complete macroscopic resec-
tion of the primary tumour and undergone complete removal of all metastatic
disease or this was planned and deemed feasible. Patients with good histo-
logical response had to be ≥5 years due to concerns of age-related toxicity
from interferon [7]. Data collection including registration characteristics and
reports on pre-operative chemotherapy, surgery and pathology had to be
received by the randomising data centre. Consent was obtained according to
national regulations. Supp_Appendix_B (supplementary Material, available at
Annals of Oncology online) describes the study organisation.
treatment
Chemotherapy for the control arm (Figure 2) was based on the standard
described in the previous largest RCT for osteosarcoma [8]. Pre-operative
treatment comprised methotrexate 12 g/m2 (M), doxorubicin 75 mg/m2
(Adriamycin, A) and cisplatin 120 mg/m2 (P). Preferred schedules were 48-h
infusion for doxorubicin and either 72-h infusion or two 4-h infusions on
separate days for cisplatin. Methotrexate was given over 4 h and folinic acid
rescue commenced at 24 h. Surgery was scheduled after two cycles of MAP,
i.e., 10 weeks after starting chemotherapy.
Biopsy-proven diagnosis of
resectable osteosarcoma
REGISTER
MAP (induction)
Surgery
RANDOMIZE RANDOMIZE
Poor
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Histological response assessment
Figure 1. EURAMOS-1 study design.
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Eligible, consenting patients with good histological response were rando-
mised to complete six cycles of MAP or MAP followed by maintenance
pegylated interferon α-2b (Ifn; Merck) at 0.5–1.0 μg/kg/week to 24 months
after starting chemotherapy. Eligible, consenting patients with poor histo-
logical response were randomised to continue standard chemotherapy with
MAP or to MAP/IE over 28 weeks, a schedule designed to deliver the same
total doses as post-operative MAP with additional ifosfamide and etoposide
(IE), agents previously demonstrating activity in osteosarcoma [9]. Ifosfa-
mide 3000 mg/m2 ×3 days, total dose 9 g/m2, was given with doxorubicin in
cycles designated as Ai, and at 2800 mg/m2 ×5 days, total dose 14 g/m2, with
etoposide 100 mg/m2 ×5 days, designated IE cycles.
The protocol detailed dose modiﬁcations to account for toxicity for all
treatments. Granulocyte growth factors were recommended but not mandated.
Dexrazoxane could be used at investigators’ discretion for reduced cardiac
function remaining in the normal range; this applied throughout in North
America but was withdrawn by the European Medicines Agency in 2011.
Response assessment was required to determine suitability for surgery
and to exclude progression (see supplementary Material, available at Annals
of Oncology online).
quality-of-life evaluation
Quality of life (QL) was assessed using self- and parent-completed question-
naires to determine short- and long-term impacts. For patients ≥16 years, QL
was assessed using EORTC QLQ-C30 questionnaire [10]. Patients <16 years
in COG centres answered the generic PedsQL questionnaire, and in Europe,
PEDQOL [11, 12]. The initial QL assessment was at week 5, then 3 months
after deﬁnitive surgery, at 18 months and 3 years after commencing therapy.
outcome measures
The primary outcome measure was event-free survival (EFS), deﬁned as time
from randomisation to the ﬁrst of: detection of local recurrence or
metastases, progression of metastatic disease, detection of secondary malig-
nancy or death from any cause. EFS was chosen because prevention of ﬁrst
recurrence is the principal goal of adjuvant treatment of osteosarcoma, given
the low rate of survival after ﬁrst recurrence. Furthermore, treatment of re-
currence is heterogeneous; treatment guidance for relapse accompanied the
protocol, but sites’ existing standard practice was accepted. Secondary
outcome measures were overall survival (OS), toxicity and QL. Toxicity was
assessed using CTCAE version 3.0 [13].
sample size calculations
We assumed 70% 3-year EFS on MAP for good response and 45% for poor
response, timed from randomisation. Each sample size was based on 5%
two-sided signiﬁcance level and 80% power. The Good Response randomisa-
tion needed 147 EFS events to detect improved 3-year EFS from 70% to 80%,
i.e., hazard ratio (HR) = 0·63 [14]. Five-year survival was estimated as 70% so
long-term analyses for survival were planned for when 147 deaths are
reported, for the same relative and absolute improvements. For poor re-
sponse, 378 events were targeted to detect improved 3-year EFS and 5-year
OS from 45% to 55% (HR = 0·75).
We anticipated 45% (567) randomised patients would have good response
and 55% (693) poor response [8]. We planned to register ∼1400 patients
over 3.5 years to randomise 1260, assuming 10% non-randomisation for in-
eligibility or non-consent. The observed non-randomisation rate was higher
and the registration target was increased to ∼2000 patients.
statistical analysis
This paper describes the full, registered patient population, including all
patients who signed the informed consent documents, up to the point of
surgery. Standard descriptive statistics are used.
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Figure 2. EURAMOS-1 treatment schedule.
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results
study participants
Between April 2005 and June 2011, 2260 patients from 326 sites
in seventeen countries were registered (supplementary Figures S1
and S2, available at Annals of Oncology online); 1164 (52%)
COG, 520 (23%) COSS, 457 (20%) EOI and 119 (5%) SSG. The
majority of patients were aged 10–19 with localised tumours of
the lower limb (Table 1) and conventional type osteosarcoma on
histology (Table 2). Males comprised 59% (1330/2260) of the
cohort; 355 (16%) had deﬁnite metastases, 161 (7%) possible
and 1722 (77%) no metastases. Of 355 patients with deﬁnite me-
tastases, 273 (77%) had lung mets only, 54 (15%) other mets
only, 22 (6%) both lung and other and 5 (1%) deﬁnite-lung and
possible other mets. Of 161 patients with possible metastases,
144 (89%) had possible lung metastases, 11 (7%) possible other
mets and 6 (4%) both. Table 1 shows baseline characteristics.
The eligibility criteria spanned children and adults ≤40 years
old. We estimated accrual as a proportion of expected age-
related osteosarcoma incidence osteosarcoma to address
whether participation was equally likely within the study age
range. In all groups, the proportion recruited from the estimated
population fell from age ≥ 15yrs in females and 19yrs in males,
such that ∼1/3 of potentially eligible patients were not registered
(supplementary Figure S3, available at Annals of Oncology
online). Figure 3 shows the CONSORT diagram.
randomisation
Randomisation was offered to eligible registered patients with
reported histological response. For those with reported good re-
sponse, 69% (716/1040) accepted the relevant randomisation
and for poor response, 58% (617/1059); one patient with good
response was erroneously randomised to the poor response
cohort and allocated MAP. The overall randomisation rate was
64% (1334/2100) for patients with known histological response.
There was some variability in proportion randomised
between groups: COSS 363/520 (70%), SSG 82/119 (69%), EOI
276/457 (60%) and COG 613/1164 (53%) (supplementary
Table S2, available at Annals of Oncology online). Patients aged
20–29 years were less frequently randomised (106/199, 53%)
than those 5–19 years (1194/1995, 60%) or >30 years (32/53,
60%). The main reason recorded for non-randomisation was
absence of consent (413/2260, 18%). Progression prior to
surgery was recorded in 176 patients (8%). Eighty-eight patients
(4%) could not be randomised because of late reporting of hist-
ology and 67 (3%) for incorrect pre-operative chemotherapy.
Patient characteristics for randomised and non-randomised
patients and by histological response are shown in Table 1.
histology
Diagnosis was conﬁrmed by reference pathologists in 2160/2209
(98%) of registered patients (Table 2). The commonest histo-
logical subtype was conventional (92%, 2033/2209), followed by
telangiectatic (4%, 96/2209), small cell (1%, 14/2209) and high-
grade surface (1%, 29/2209). Thirty-one patients were deemed
ineligible post-registration based on reference histological
review of the biopsy. Biopsy details remain unavailable for 51
patients (2%). In 1917 patients with reference pathologist
assessment of both diagnostic biopsy and resected specimen, the
classiﬁcation was different for 75 (4%) patients. Of these, 36/75
were re-classiﬁed as different subtypes of osteosarcoma, 15/75 as
conventional, 13/75 as telangiectatic, 6/75 as high-grade surface
osteosarcoma and 5/75 were ineligible.
Pathological assessment of histological response to pre-opera-
tive chemotherapy was available for 1975/2012 patients; 979
reported a good response and 996 a poor response. The re-
sponse rate of good histological response to MAP was 50%
overall, ranging from 46% (433/949) COG, to 53% COSS (265/
499), 53% SSG (58/110) and 54% EOI (223/417).
chemotherapy
Ninety-four percent registered patients (2123/2248) completed
two cycles of MAP pre-operatively. Median received pre-opera-
tive dose for doxorubicin was 149 mg/m2 (target 150 mg/m2),
239 mg/m2 cisplatin (target 240 mg/m2) and 46.8 g/m2 high-
dose methotrexate (target 48 g/m2). Median time from registra-
tion in EURAMOS-1 to starting chemotherapy was 0 days
[interquartile range (IQR) -2; 0]. Median time from start of
chemotherapy to surgery was 82 days (IQR 76; 90). Median
time from surgery to starting post-operative chemotherapy for
randomised patients was 18 days (IQR 14; 24).
The pre-operative toxicities reported were as expected.
Table 3 shows the worst reported toxicity. CTCAE grade 3–4
toxicity was common: 1863/2234 (83%) neutropenia; 1292/2237
(58%) infective complications; 1122/2238 (50%) thrombocyto-
penia; 544/1989 (27%) mucositis; grade 1 or 2 mucositis was
reported in a further 21% (427/1989) and 28% (557/1989), re-
spectively. Severe renal, neurological and left ventricular dys-
functions were uncommon.
There were three treatment-related deaths (3/2260, 0.13%)
during the pre-operative period, two from infective complica-
tions and one from toxic epidermal necrolysis secondary to
methotrexate.
surgery
The amputation rate, including rotationplasty, was 17% (346/
2054), ranging from 16% (169/1045, COG) to 19% (22/114,
SSG) (Table 4). Macroscopic clearance of the primary tumour
was reported in 99% (2035/2051). There were three post-opera-
tive deaths: one patient died from embolic complications on the
third post-operative day, a second from pneumonia with
respiratory failure on day 29 and a third from infection compli-
cated by multisystem failure 48 days after surgery.
data completeness and follow-up
Long-term event data were sought in all patients, regardless of
randomisation. In 15 February 2013, 1455/1566 (93%) had data
within the previous 14 months; death and loss to follow-up were
reported in 526/2260 and 168/2260 patients, respectively.
Long-term event data from the full cohort, including second
malignancy data, will be reported with further follow-up.
discussion
Osteosarcoma therapy was revolutionised by the introduction of
adjuvant combination chemotherapy, in the 1970s, but has
 | Whelan et al. Volume 26 | No. 2 | February 2015
original articles Annals of Oncology
Table 1. Baseline characteristics at registration
Response Randomised Not randomised Overall
Good Poor Good Poor Not known
N % N % N % N % N % N %
Sex
Male 421 59 365 59 190 59 264 60 90 56 1330 59
Female 295 41 253 41 134 41 178 40 70 44 930 41
Missing 0 n/a 0 n/a 0 n/a 0 n/a 0 n/a 0 n/a
Age at registration
0–4 1 0 1 0 6 2 3 1 0 0 11 0
5–9 102 14 94 15 48 15 45 10 21 13 310 14
10–14 305 43 217 35 130 40 167 38 59 37 878 39
15–19 258 36 218 35 113 35 166 38 54 34 809 36
20–24 28 4 52 8 19 6 37 8 17 11 153 7
25–29 11 2 15 2 5 2 10 2 5 3 46 2
30–34 1 0 9 1 3 1 5 1 1 1 19 1
35–39 10 1 11 2 0 0 7 2 2 1 30 1
40 0 0 1 0 0 0 2 0 1 1 4 0
Median (quartiles) 14 (11, 16) 14 (11, 17) 14 (11, 16) 15 (12, 17) 15 (11, 17) 14 (11, 17)
Min–max 4–38 4–40 4–32 4–40 5–40 4–40
Missing 0 n/a 0 n/a 0 n/a 0 n/a 0 n/a 0 n/a
Site and location
Proximal femur or humerus 83 12 77 13 44 14 68 16 21 14 293 13
Other limb site 617 86 508 82 265 84 340 78 107 70 1837 82
Axial or skeletal 16 2 31 5 7 2 30 7 24 16 108 5
Missing 0 n/a 2 n/a 8 n/a 4 n/a 8 n/a 22 n/a
Pathological fracture
No at diagnosis 629 88 545 89 272 86 387 88 131 86 1964 88
Yes at diagnosis 86 12 69 11 44 14 52 12 22 14 273 12
Missing 1 n/a 4 n/a 8 n/a 3 n/a 7 n/a 23 n/a
Localised disease
Yes (no mets) 567 79 491 80 239 76 324 74 101 66 1722 77
Possible mets 63 9 48 8 19 6 26 6 5 3 161 7
No (yes mets) 86 12 76 12 58 18 88 20 47 31 355 16
Missing 0 n/a 3 n/a 8 n/a 4 n/a 7 n/a 22 n/a
Lung metastases
No 583 81 505 82 247 78 340 77 107 70 1782 80
Possibly 62 9 46 7 16 5 26 6 6 4 156 7
Yes 71 10 64 10 53 17 73 17 40 26 301 13
Missing 0 n/a 3 n/a 8 n/a 3 n/a 7 n/a 21 n/a
Other metastases
No 691 97 590 96 304 97 414 95 141 92 2140 96
Possibly 5 1 8 1 4 1 2 0 3 2 22 1
Yes 20 3 18 3 7 2 22 5 9 6 76 3
Missing 0 n/a 2 n/a 9 n/a 4 n/a 7 n/a 22 n/a
Duration of symptoms (days)
Median (quartiles) 8 (4, 13) 8 (4, 14) 8 (4, 12) 10 (6, 16) 9 (6, 16) 8 (4, 14)
Min–max 0–78 0–312 0–104 0–260 0–104 0–312
Missing 85 n/a 68 n/a 43 n/a 59 n/a 30 n/a 285 n/a
Group
COG 300 42 313 51 180 56 256 58 115 72 1164 52
COSS 206 29 157 25 60 19 78 18 19 12 520 23
EOI 161 22 115 19 73 23 89 20 19 12 457 20
SSG 49 7 33 5 11 3 19 4 7 4 119 5
Total 716 100 618 100 324 100 442 100 160 100 2260 100
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improved little since. The cost of seeking cure is exceptionally
high as patients receive particularly complex and toxic chemo-
therapy regimens, plus disabling surgery. The single new treat-
ment which has emerged, mifamurtide (MTP-PE), has been the
subject of considerable controversy and its availability varies
internationally, due to disagreements about interpretation of the
available clinical data and cost.
While many studies have been undertaken for osteosarcoma,
they are often characterised by being non-randomised or, if ran-
domised, by their long accrual periods [15–18]. This was the
background against which we joined together to attempt to
develop new paradigms for treating this disease.
The EURAMOS group chose to undertake a large cohort
study, embedding two randomised comparisons as our ﬁrst col-
laboration [6]. The two questions chosen for this ﬁrst study stra-
tiﬁed post-operative treatment according to the histologically
assessed response to pre-operative chemotherapy. It assessed
maintenance therapy in patients with a better prognosis (Good
Response) [19] and intensiﬁcation in patients with poorer prog-
nosis (Poor Response) [9, 20–22]. These important questions
were amenable to a relatively simple trial design. However, the
agents chosen highlight the paucity of new or investigational
products appropriate to include in phase III trials.
EURAMOS-1 has been successfully executed. The study was
developed through a commitment to collaboration between four
well-established study groups. With 1334 patients with resect-
able osteosarcoma randomised, it doubled the size of the previ-
ous largest RCT in this population and accrual was completed
in around 6 years. Other indicators of quality and safety for a
trial on this scale are reassuring. Concordance with protocol
chemotherapy was excellent. Toxicities were consistent with pre-
vious experience of these agents. The treatment-related death
Table 2. Pathology at diagnostic biopsy and surgery
Diagnostic
biopsy
Resected
specimen
N % N %
Data available
Yes 2209 98 2012 89
No 51 2 248 11
Type of pathologist
Reference 2160 98 1951 97
Local only 49 2 61 3
Histology
Conventional 2033 92 1832 93
Telangiectatic 96 4 90 5
Small cell 14 1 7 0
High-grade surface 29 1 28 1
Secondary 0 0 0 0
Unclassiﬁed osteosarcoma 2 0 1 0
Ineligible 31 1 15 1
Not assessable 0 0 2 0
Info missing from the form 4 n/a 37 n/a
Excision of tumour
Marginal n/a n/a 264 13
Wide n/a n/a 1474 74
Radical n/a n/a 222 11
Intra-lesional n/a n/a 26 1
Not known n/a n/a 19 1
Info missing from the form n/a n/a 7 n/a
Histological response
Good (<10% viable tumour) n/a n/a 979 50
Poor (≥10% viable tumour) n/a n/a 996 50
Info missing from the form n/a n/a 37 n/a
Total 2209 100 2012 100
2260 patients registered to the trial
Registration
2209 patients with available data
51 missing forms
Diagnostic biopsy
2248 patients started preoperative MAP
12 missing forms
Preoperative MAP
2012 patients with available data
248 missing forms
1334 randomised
926 not randomised
1455 (93%) recent follow-up
last contact less than 14 months ago
111 (7%) late follow-up
last contact more than 14 months ago
168 lost to follow-up
526 died
979 patients: good responders
996 patients: poor responders
37 patients: histological response missing
**histological response is reported on resected specimen
and randomisation forms
2258 patients with available data
2 patients withdrew, due to ineligibility
1041 good responders: 717* randomised (69%)
1059 poor responders: 617 randomised (58%)
160 histological response not known
*1 good responder entered poor responders randomisation
**histological response is reported on resected specimen
and randomisation forms
Resected specimen**
Randomisation**
Follow-up
2054 patients with available data
206 missing forms
Surgery
Figure 3. EURAMOS-1 CONSORT diagram.
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rate of 0.18% from pre-operative chemotherapy is at the lower
end of the range previously reported.
In other areas, the study has highlighted where improvement
is needed. This was the ﬁrst publicly-funded pan-European clin-
ical trial to be activated after European countries implemented
the European Clinical Trials Directive, which created new chal-
lenges [23]. There were limits to the accessibility of the trial for
osteosarcoma patients. We were unable to open EURAMOS-1
in some countries that wished to participate either because of
regulatory constraints or insufﬁcient funding. Moreover, even
though we used age eligibility criteria which allowed inclusion
of all patients aged <40 years, the proportion of potentially eli-
gible patients fell with increasing age beginning from late
teenage years, a phenomenon consistent with accrual rates seen
for other cancers in young adults [24, 25].
The feasibility of delivering intensive chemotherapy for a rare
cancer in multiple centres within a Good Clinical Practice
framework is amply demonstrated here. However, it is also clear
that the treatment burden of MAP is exceptionally high,
reﬂected in levels of grade 3–4 haematological and non-haem-
atological toxicity. While the link between increased toxicity and
improved survival from osteosarcoma remains to be unravelled
[26], future approaches must look to reduce this burden as well
as improve efﬁcacy.
At the time of trial planning, few data were available to guide
a sample size calculation to accurately estimate randomisation
rates and these were markedly lower than expected, which con-
tributed to a decision to expand registration targets from 1400
to over 2000. Information collected on reasons for non-random-
isation has been relatively non-informative but anecdotally,
young people expressed a reluctance to risk allocation to experi-
mental treatments that were substantially longer than the stand-
ard MAP schedule. Further investigation of this important area
is needed [27]. Greater patient involvement at the design stage
may help in the future.
First results of the Good Response randomisation have been
presented orally [28], with a clear demonstration that large-scale
practice-changing randomised, controlled trials can be under-
taken in rare cancers by extending the traditional boundaries of
collaboration. From EURAMOS-1, we are growing a wider col-
laboration with groups willing to work together. A successor
study has not yet emerged despite willingness by investigators
and other trials groups joining the collaboration to face the
Table 3. Worst pre-operative MAP toxicity
Worst toxicity grade with
pre-operative MAP
Randomised Not randomised Overall
Good Poor Good Poor Not known
N % N % N % N % N % N %
Grade 0 7 1 10 2 4 1 3 1 8 5 32 1
Grade 1 12 2 8 1 5 2 9 2 5 3 39 2
Grade 2 19 3 40 6 9 3 18 4 9 6 95 4
Grade 3 109 15 79 13 36 11 79 18 28 18 331 15
Grade 4 569 79 480 78 267 82 331 75 95 59 1742 77
Grade 5 0 0 0 0 1 0 0 0 2 1 3 0
Not assessed 0 n/a 1 n/a 1 n/a 1 n/a 1 n/a 4 n/a
Not reported on CRF 0 n/a 0 n/a 1 n/a 1 n/a 12 n/a 14 n/a
Total 716 100 618 100 324 100 442 100 160 100 2260 100
Three deaths were treatment-related (two from infective complications and one from toxic epidermal necrolysis secondary to methotrexate) and three
occurred after surgery.
Percentages exclude the ‘not assessed’ and ‘not reported’ rows.
Excludes three deaths occurred after surgery. Of those patients, one Good Responder had worst toxicity of grade 1; one poor responder had worst
toxicity of grade 3 and one person with unknown histological response had a worst toxicity of grade 4.
Table 4. Surgical details
Data source Total
N %
Surgical data
Received 2054 91
Not received 206 9
Pathological fracture at surgery
No 1881 92
Yes 169 8
Missing on surgery form 4 n/a
Surgical procedure
Amputation 213 10
Disarticulation 30 1
Rotationplasty 103 5
Resection + reconstruction 1571 77
Resection only 91 4
Other 45 2
Missing 1 n/a
Macroscopic clearance achieved
Yes 2035 99
No, despite surgery 16 1
Missing 3 n/a
Total 2054 100
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formidable regulatory and ﬁnancial challenges which must be
overcome. The absence of testable new innovations in this
disease is a cause for major concern and even more apparent
now we have established a successful test platform.
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